 Proactive Investors USA & Canada | Isotechnika strikes licensing deal with Vifor Pharma, stocks rise Proactive Investors USA & Canada Isotechnika's chief executive, Robert Foster, said: “While the successful development of voclosporin for the prevention of kidney transplant rejection remains our primary focus, we believe the expansion of our platform beyond that indication via ... Isotechnika Enters Into Development and Commercialization License Agreement ... |
